10x Genomics unveiled the next generation of its Chromium Flex assay: an automation‑compatible, plate‑based workflow that enables 384‑sample multiplexing and the capacity to process up to 100 million cells per week. The company positioned the product as enabling large‑scale single‑cell studies—including high‑sample translational programs and population‑scale projects—at lower per‑sample cost. 10x said the assay integrates with automated partitioning and supports high sensitivity across varied sample types, including FFPE tissue. Early access customers reportedly include academic and industry groups running high‑throughput immunology, oncology and CRISPR screens. The launch addresses a persistent bottleneck in single‑cell adoption—scale and cost—and could push more translational programs to adopt single‑cell and spatial readouts in late‑stage discovery and early clinical biomarker work.